Nivolunix 40 mg (Nivolumab) Injection

Nivolunix 40 (Nivolumab) is an immune checkpoint inhibitor that helps the body's immune system identify and attack cancer cells more effectively. It is used in the management of certain advanced or metastatic malignancies under specialist supervision.

Therapeutic Effects:

• Enhances T-cell mediated immune response against cancer cells.
• Blocks the programmed death-1 (PD-1) pathway to restore anti-tumor activity.
• May help slow disease progression in eligible patients.
• Supports long-term disease control in selected cancer types.

Uses:

• Advanced or metastatic melanoma
• Non-small cell lung cancer (NSCLC)
• Renal cell carcinoma (kidney cancer)
• Classical Hodgkin lymphoma
• Squamous cell carcinoma of the head and neck
• Urothelial carcinoma
• Esophageal cancer and other approved oncology indications

Active Ingredient:

• Nivolumab INN

Strength:

• 40 mg / 4 mL

Dosage Form:

• Concentrate for Solution for Intravenous Infusion

Composition:

Each 4 mL vial contains:

• Nivolumab INN ............ 40 mg
• Excipients ............ q.s. to 4 mL

Note: The complete list of inactive ingredients should be reviewed from the official prescribing information before administration.

Recommended Administration:

• Administered as an intravenous infusion by qualified healthcare professionals experienced in cancer treatment.
• The dosage schedule depends on the type of cancer, body weight, treatment protocol, and clinical response.

General Guidance:

• Use only under the supervision of an oncologist.
• Infuse according to established institutional protocols.
• Patients should be monitored for infusion-related reactions and immune-mediated adverse events during treatment.

Missed Dose:

• If a scheduled infusion appointment is missed, contact the treating healthcare provider promptly to arrange the next dose.
• Do not attempt to self-administer or alter the dosing schedule.

Important Instructions:

• Not intended for intramuscular or subcutaneous administration.
• Follow all recommended laboratory monitoring requirements during therapy.
• Dose modifications or treatment interruption may be necessary based on tolerability and adverse reactions.

Disclaimer: The exact dosage regimen should always be determined by the treating physician based on approved prescribing guidelines and individual patient factors.